Trifolium Flavonoids Overcome Gefitinib Resistance of Non-Small-Cell Lung Cancer Cell by Suppressing ERK and STAT3 Signaling Pathways

Gefitinib is a tyrosine kinase inhibitor of EGFR (epidermal growth factor receptor) and represents the first-line treatment for EGFR mutation patients with NSCLC (non-small-cell lung cancer) therapeutics. However, NSCLC patients are inclined to develop acquired gefitinib drug resistance through nowa...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Zhiqiang, Xu, Bin, Yu, Zhiyi, He, Qin, Hu, Zhuyuan, Zhou, Shishi, Chen, Meiqin, Zhu, Liang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7603574/
https://www.ncbi.nlm.nih.gov/pubmed/33150167
http://dx.doi.org/10.1155/2020/2491304

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7603574/
https://www.ncbi.nlm.nih.gov/pubmed/33150167
http://dx.doi.org/10.1155/2020/2491304

Ejemplares similares